CEBPD and metabolic dysfunction-associated steatohepatitis: Indeed, a markedly increased abundance of CEBPD was observed in the livers of NASH patients and HFHC/WTDF diet-treated rodent models as compared to those of non-steatosis donors and NCD diet-fed control mice (Fig. 1d).